OncoMatch/Clinical Trials/NCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Is NCT06584006 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Thymalfasin for and Recombinant Human Interleukin-2 Injections for hematological malignancy.
Treatment: Thymalfasin for · Recombinant Human Interleukin-2 Injections — To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Within 8 days after chemotherapy for lymphoma and within 14 days after chemotherapy for AML
Cannot have received: immunosuppressive treatment (cyclosporine, corticosteroids, ruxolitinib, JAK1/2 inhibitors)
Immunosuppressive treatment (such as cyclosporine, corticosteroids, ruxolitinib, JAK1/2 inhibitors, etc.) within the past 5 days
Cannot have received: allogeneic hematopoietic stem cell transplantation
Patients who have undergone allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
Tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils <1.0×10^9/L, HB<70g/L, PLT<50×10^9/L) [excluded]
Kidney function
Estimated creatinine clearance rate ≥ 30 mL/min.
Liver function
AST and ALT ≤ 3.0 x ULN. Bilirubin ≤ 1.5 x ULN.
Estimated creatinine clearance rate ≥ 30 mL/min. AST and ALT ≤ 3.0 x ULN. Bilirubin ≤ 1.5 x ULN. Tumor involvement in the bone marrow leading to hematopoietic suppression (neutrophils <1.0×10^9/L, HB<70g/L, PLT<50×10^9/L) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06584006 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, immunosuppressive treatment, allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify